1
|
Luzala MM, Muanga CK, Kyana J, Safari JB, Zola EN, Mbusa GV, Nuapia YB, Liesse JMI, Nkanga CI, Krause RWM, Balčiūnaitienė A, Memvanga PB. A Critical Review of the Antimicrobial and Antibiofilm Activities of Green-Synthesized Plant-Based Metallic Nanoparticles. NANOMATERIALS (BASEL, SWITZERLAND) 2022; 12:1841. [PMID: 35683697 PMCID: PMC9182092 DOI: 10.3390/nano12111841] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Revised: 04/03/2022] [Accepted: 04/05/2022] [Indexed: 02/01/2023]
Abstract
Metallic nanoparticles (MNPs) produced by green synthesis using plant extracts have attracted huge interest in the scientific community due to their excellent antibacterial, antifungal and antibiofilm activities. To evaluate these pharmacological properties, several methods or protocols have been successfully developed and implemented. Although these protocols were mostly inspired by the guidelines from national and international regulatory bodies, they suffer from a glaring absence of standardization of the experimental conditions. This situation leads to a lack of reproducibility and comparability of data from different study settings. To minimize these problems, guidelines for the antimicrobial and antibiofilm evaluation of MNPs should be developed by specialists in the field. Being aware of the immensity of the workload and the efforts required to achieve this, we set out to undertake a meticulous literature review of different experimental protocols and laboratory conditions used for the antimicrobial and antibiofilm evaluation of MNPs that could be used as a basis for future guidelines. This review also brings together all the discrepancies resulting from the different experimental designs and emphasizes their impact on the biological activities as well as their interpretation. Finally, the paper proposes a general overview that requires extensive experimental investigations to set the stage for the future development of effective antimicrobial MNPs using green synthesis.
Collapse
Affiliation(s)
- Miryam M. Luzala
- Laboratory of Pharmaceutics and Phytopharmaceutical Drug Development, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo; (M.M.L.); (C.K.M.); (E.N.Z.); (C.I.N.)
| | - Claude K. Muanga
- Laboratory of Pharmaceutics and Phytopharmaceutical Drug Development, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo; (M.M.L.); (C.K.M.); (E.N.Z.); (C.I.N.)
| | - Joseph Kyana
- Department of Pharmacy, Faculty of Medecine and Pharmacy, University of Kisangani, Kisangani XI B.P. 2012, Democratic Republic of the Congo;
| | - Justin B. Safari
- Department of Pharmacy, Faculty of Pharmaceutical Sciences and Public Health, Official University of Bukavu, Bukavu B.P. 570, Democratic Republic of the Congo;
- Department of Chemistry, Faculty of Science, Rhodes University, P.O. Box 94, Makhana 6140, South Africa
| | - Eunice N. Zola
- Laboratory of Pharmaceutics and Phytopharmaceutical Drug Development, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo; (M.M.L.); (C.K.M.); (E.N.Z.); (C.I.N.)
| | - Grégoire V. Mbusa
- Centre Universitaire de Référence de Surveillance de la Résistance aux Antimicrobiens (CURS-RAM), Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo; (G.V.M.); (J.-M.I.L.)
- Laboratory of Experimental and Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo
| | - Yannick B. Nuapia
- Laboratory of Toxicology, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo;
| | - Jean-Marie I. Liesse
- Centre Universitaire de Référence de Surveillance de la Résistance aux Antimicrobiens (CURS-RAM), Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo; (G.V.M.); (J.-M.I.L.)
- Laboratory of Experimental and Pharmaceutical Microbiology, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo
| | - Christian I. Nkanga
- Laboratory of Pharmaceutics and Phytopharmaceutical Drug Development, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo; (M.M.L.); (C.K.M.); (E.N.Z.); (C.I.N.)
| | - Rui W. M. Krause
- Department of Chemistry, Faculty of Science, Rhodes University, P.O. Box 94, Makhana 6140, South Africa
- Center for Chemico- and Bio-Medicinal Research (CCBR), Faculty of Science, Rhodes University, P.O. Box 94, Makhana 6140, South Africa
| | - Aistė Balčiūnaitienė
- Lithuanian Research Centre for Agriculture and Forestry, Institute of Horticulture, 54333 Babtai, Lithuania;
| | - Patrick B. Memvanga
- Laboratory of Pharmaceutics and Phytopharmaceutical Drug Development, Faculty of Pharmaceutical Sciences, University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo; (M.M.L.); (C.K.M.); (E.N.Z.); (C.I.N.)
- Department of Pharmacy, Faculty of Medecine and Pharmacy, University of Kisangani, Kisangani XI B.P. 2012, Democratic Republic of the Congo;
- Department of Pharmacy, Faculty of Pharmaceutical Sciences and Public Health, Official University of Bukavu, Bukavu B.P. 570, Democratic Republic of the Congo;
- Centre de Recherche et d’Innovation Technologique en Environnement et en Sciences de la Santé (CRITESS), University of Kinshasa, Kinshasa XI B.P. 212, Democratic Republic of the Congo
| |
Collapse
|
2
|
Improvement of synaptic plasticity by nanoparticles and the related mechanisms: Applications and prospects. J Control Release 2022; 347:143-163. [PMID: 35513209 DOI: 10.1016/j.jconrel.2022.04.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 04/27/2022] [Accepted: 04/28/2022] [Indexed: 11/20/2022]
Abstract
Synaptic plasticity is an important basis of learning and memory and participates in brain network remodelling after different types of brain injury (such as that caused by neurodegenerative diseases, cerebral ischaemic injury, posttraumatic stress disorder (PTSD), and psychiatric disorders). Therefore, improving synaptic plasticity is particularly important for the treatment of nervous system-related diseases. With the rapid development of nanotechnology, increasing evidence has shown that nanoparticles (NPs) can cross the blood-brain barrier (BBB) in different ways, directly or indirectly act on nerve cells, regulate synaptic plasticity, and ultimately improve nerve function. Therefore, to better elucidate the effect of NPs on synaptic plasticity, we review evidence showing that NPs can improve synaptic plasticity by regulating different influencing factors, such as neurotransmitters, receptors, presynaptic membrane proteins and postsynaptic membrane proteins, and further discuss the possible mechanism by which NPs improve synaptic plasticity. We conclude that NPs can improve synaptic plasticity and restore the function of damaged nerves by inhibiting neuroinflammation and oxidative stress, inducing autophagy, and regulating ion channels on the cell membrane. By reviewing the mechanism by which NPs regulate synaptic plasticity and the applications of NPs for the treatment of neurological diseases, we also propose directions for future research in this field and provide an important reference for follow-up research.
Collapse
|
3
|
Raj S, Sasidharan S, Tripathi T, Saudagar P. Biofunctionalized Chrysin-conjugated gold nanoparticles neutralize Leishmania parasites with high efficacy. Int J Biol Macromol 2022; 205:211-219. [PMID: 35183598 DOI: 10.1016/j.ijbiomac.2022.02.047] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Revised: 02/02/2022] [Accepted: 02/09/2022] [Indexed: 12/18/2022]
Abstract
Current treatments for leishmaniasis involve various drugs, including miltefosine and amphotericin B, which are associated with several side effects and high costs. Long-term use of these drugs may lead to the development of resistance, thereby reducing their efficiency. Chrysin (CHY) is a well-known, non-toxic flavonoid with antioxidant, antiviral, anti-inflammatory, anti-cancer, hepatoprotective, and neuroprotective properties. Recently we have shown that CHY targets the MAP kinase 3 enzyme of Leishmania and neutralizes the parasite rapidly. However, CHY is associated with low bioavailability, poor absorption, and rapid excretion issues, limiting its usage. In this study, we developed and tested a novel CHY-gold nanoformulation with improved efficacy against the parasites. The reducing power of CHY was utilized to reduce and conjugate with gold nanoparticles. Gold nanoparticles, which are already known for their anti-leishmanial properties, along with conjugated CHY, exhibited a decreased parasite burden in mammalian macrophages. Our findings showed that this biofunctionalized nanoformulation could be used as a potential therapeutic tool against leishmaniasis.
Collapse
Affiliation(s)
- Shweta Raj
- Department of Biotechnology, National Institute of Technology-Warangal, Warangal 506004, India
| | - Santanu Sasidharan
- Department of Biotechnology, National Institute of Technology-Warangal, Warangal 506004, India
| | - Timir Tripathi
- Molecular and Structural Biophysics Laboratory, Department of Biochemistry, North-Eastern Hill University, Shillong 793022, India
| | - Prakash Saudagar
- Department of Biotechnology, National Institute of Technology-Warangal, Warangal 506004, India.
| |
Collapse
|
4
|
Catalano PN, Chaudhary RG, Desimone MF, Santo-Orihuela PL. A Survey on Analytical Methods for the Characterization of Green Synthesized Nanomaterials. Curr Pharm Biotechnol 2021; 22:823-847. [PMID: 33397235 DOI: 10.2174/1389201022666210104122349] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Revised: 11/03/2020] [Accepted: 11/12/2020] [Indexed: 11/22/2022]
Abstract
Nowadays, nanotechnologies are well established and the uses of a great variety of nanomaterials show exponential growth. The development of green synthesis procedures experienced a great development thanks to the contribution of researchers of diverse origins. The versatility of green chemistry allows producing a wide range of organic and inorganic nanomaterials with numerous promising applications. In all cases, it is of paramount importance to carefully characterize the resulting nanomaterials because their properties will determine their correct performance to accomplish the function to which they were synthesized or even their detrimental effects like nanotoxicological behavior. This review provides an overview of frequently employed characterization methods and their applications for green synthesized nanomaterials. However, while several different nanoscale materials and their associated green construction methodology are being developed, other important techniques would be extensively incorporated into this field soon. The aim is to encourage researchers in the field to employ a variety of these techniques for achieving an exhaustive characterization of new nanomaterials and for contributing to the development of validated green synthesis procedures.
Collapse
Affiliation(s)
- Paolo N Catalano
- Departamento de Micro y Nanotecnologia, Instituto de Nanociencia y Nanotecnología, CNEA-CONICET, Av. General Paz 1499 (1650), San Martin, Argentina
| | - Ratiram G Chaudhary
- Post Graduate Department of Chemistry, S.K. Porwal College, Kamptee 441001, India
| | - Martín F Desimone
- Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Tecnicas (CONICET), Instituto de la Quimica y Metabolismo del Farmaco (IQUIMEFA), Facultad de Farmacia y Bioquimica Junin 956, Piso 3 (1113), Buenos Aires, Argentina
| | - Pablo L Santo-Orihuela
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Junin 956, Piso 3 (1113), Buenos Aires, Argentina
| |
Collapse
|